ShareHope Medicine Valuation

Q: What is the Fair Price of 8403 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

8403 (NT$28.75) is trading above our estimate of [[fair value]] (NT$9.91)

Is 8403 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 8403 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 8403 (NT$28.75) is trading above our estimate of fair value (NT$9.91)

Significantly Below Fair Value: 8403 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 8403?

Key metric: As 8403 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 8403. This is calculated by dividing 8403's market cap by their current earnings.
What is 8403's PE Ratio?
PE Ratio	24x
Earnings	NT$157.13m
Market Cap	NT$3.77b

8403 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.1x
Enterprise Value/EBITDA	16.9x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 8403's PE Ratio compare to its peers?

The above table shows the PE ratio for 8403 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	59.3x
1784 BIONET	84.3x	n/a	NT$4.7b
6637 Medical Imaging	17.8x	n/a	NT$2.5b
6879 TCI GENE	49.3x	n/a	NT$1.3b
6665 Healthconn	85.8x	n/a	NT$941.0m
8403 ShareHope Medicine	24x	n/a	NT$3.8b

Price-To-Earnings vs Peers: 8403 is good value based on its Price-To-Earnings Ratio (24x) compared to the peer average (59.3x).

Price to Earnings Ratio vs Industry

How does 8403's PE Ratio compare vs other companies in the Asian Healthcare Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 8403 is expensive based on its Price-To-Earnings Ratio (24x) compared to the Asian Healthcare industry average (21.2x).

Price to Earnings Ratio vs Fair Ratio

What is 8403's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

8403 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	24x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 8403's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Universal Vision Biotechnology

NT$18.3b

Operates a chain of eye care clinics in Taiwan and China.

3218

NT$215.50

1.9%

-27.1%

Hi-Clearance

NT$6.2b

Supplies medical devices for the renal, cardiac, radiation, dental, oral surgery, and metabolism markets in Taiwan.

1788

NT$138.50

0.4%

2.6%

Pacific Hospital Supply

NT$6.5b

Manufactures, processes, and sells medical disposable products and equipment in Taiwan.

4126

NT$89.00

-0.3%

6.0%